Esophageal VaricesNCT07464522
Non-invasive Predictors of Esophageal Varices and Their Correlation to Upper Endoscopic Findings
An observational study of Esophageal Varices and Portal Hypertension, run by Assiut University.
Trial summary
The goal of this observational study: To evaluate the diagnostic accuracy of non-invasive markers in predicting the presence and grading of esophageal varices in children with portal hypertension. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Esophageal Varices, Portal Hypertension
- How many people
- 51 participants
- Where
- No sites listed yet
- Study dates
- 20 Mar 2026to 20 May 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Portal hypertension in children will be defined using non-invasive clinical, laboratory, and Doppler-ultrasound criteria, in the context of clinical presentation, without invasive pressure measurements. Patients with portal hypertension will be classified as: patients with hepatic causes and patients with extrahepatic causes All patients included in this study will be subjected to: * 1. Full Clinical History * 2. Detailed Clinical Examination * 3. Laboratory Investigations * 4. Abdominal Ultrasound * 5. Doppler Ultrasound * 6.Non-invasive predictive scores for esophageal varices The following parameters will be assessed: * Platelet count (PLT) * Spleen size z-score * Platelet count to spleen size ratio: * CPR (Calculated Platelet Ratio) * APRI (AST to Platelet Ratio Index) * FIB-4 * King score * MELD and PELD scores will be analyzed as secondary variables and not as primary predictors of esophageal varices -7. Esophagogastroduodenoscopy (EGD)
Who may be able to join
- Patients aged less than 18 years diagnosed with portal hypertension either due to hepatic or extrahepatic causes
Who cannot join
- Active variceal bleeding at presentation (hemodynamic instability affects platelet/spleen parameters).
- Previous history of variceal bleeding or endoscopic intervention (band ligation/sclerotherapy).
- Prior surgical portosystemic shunts or Transjugular Intrahepatic Portosystemic Shunt (TIPS).
- Current use of vasoactive drugs for primary prophylaxis (e.g., Non-selective beta-blockers).
- Systemic infections or hematological disorders causing independent thrombocytopenia or splenomegaly (to avoid confounding the platelet/spleen ratio).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Non-invasive Predictors of Esophageal Varices in Pediatric Portal Hypertension and Their Correlation to Upper Endoscopic Findings
The goal of this observational study:
- To evaluate the diagnostic accuracy of non-invasive markers in predicting the presence and grading of esophageal varices in children with portal hypertension.
- To correlate these non-invasive markers with the severity of portal hypertension and the grade of esophageal varices to identify patients at high risk of bleeding.
- To propose a defined protocol for screening esophageal varices in those children.
Read the detailed description
Portal hypertension in children represents a major hepatobiliary disorder characterized by abnormally elevated pressure within the portal venous system, typically defined as a clinically significant increase in portal venous pressure leading to the formation of portosystemic collaterals and complications such as splenomegaly, hypersplenism, gastroesophageal varices, and portal hypertensive gastropathy. Although direct portal pressure measurement is rarely performed in pediatrics, portal hypertension is generally inferred when clinical, laboratory, and radiologic findings indicate increased resistance to portal blood flow. Doppler ultrasonography demonstrating reduced portal vein velocity, increased portal vein diameter, or reversal of flow is widely accepted as a non-invasive surrogate of elevated portal pressure in children.
The true global incidence of pediatric portal hypertension remains difficult to determine, partly because of variations in underlying etiologies across different regions. Nevertheless, portal hypertension is a major cause of upper gastrointestinal bleeding in childhood, accounting for a significant proportion of variceal hemorrhage admissions in tertiary pediatric gastroenterology units. In developing countries, extrahepatic portal vein obstruction (EHPVO) constitutes the leading cause, whereas intrahepatic diseases dominate in high-income nations. With increasing survival of children with chronic liver diseases and improved neonatal care, the burden of pediatric portal hypertension has been rising over the past two decades, underscoring the need for improved strategies for early diagnosis and prevention of complications.
Causes of portal hypertension in children are traditionally divided into extrahepatic and intrahepatic categories. EHPVO is among the most frequent etiologies in many low- and middle-income countries and is commonly associated with neonatal umbilical vein catheterization, sepsis, dehydration, thrombophilia, abdominal surgery, and congenital portal vein malformations. These children often present at a young age with splenomegaly and hypersplenism despite preserved liver synthetic function. Intrahepatic causes include cholestatic liver diseases such as biliary atresia-which remains a leading indication for pediatric liver transplantation-congenital hepatic fibrosis, autoimmune hepatitis, Wilson disease, alpha-1-antitrypsin deficiency, metabolic disorders, and chronic viral hepatitis.
Progressive hepatocellular injury, fibrosis, and architectural distortion increase resistance to portal flow and lead to portal hypertension in these conditions.
Diagnosis of portal hypertension in children relies on a combination of clinical evaluation, laboratory abnormalities, and imaging findings. Splenomegaly is the most common and often earliest clinical manifestation. Laboratory markers such as thrombocytopenia reflect hypersplenism secondary to splenic sequestration. Doppler ultrasound is the first-line diagnostic tool, providing information on portal vein diameter, patency, flow velocity, degree of congestion, presence of cavernous transformation, and detection of portosystemic collaterals. Additional imaging modalities such as contrast-enhanced CT, MR angiography, and elastography may assist in defining the underlying cause and assessing liver stiffness. Endoscopy remains the gold standard for confirming and grading esophageal varices; however, its invasive nature and the need for anesthesia in children limit its use as a routine screening tool. Consequently, numerous non-invasive predictors such as platelet count, spleen size, platelet-to-spleen ratio, APRI, liver stiffness, and composite scores have been investigated to reduce reliance on endoscopy.
Complications of pediatric portal hypertension vary according to etiology and disease stage. Esophageal and gastric varices represent the most feared sequelae, with variceal hemorrhage contributing significantly to morbidity and mortality. Other complications include portal hypertensive gastropathy, hypersplenism, ascites, growth failure, minimal hepatic encephalopathy, and portal biliopathy in cases of long-standing EHPVO. Extrahepatic consequences such as portopulmonary hypertension and hepatopulmonary syndrome are increasingly recognized in children with chronic liver disease and may adversely affect prognosis, transplant eligibility, and overall quality of life.
The early diagnosis of portal hypertension and timely identification of esophageal varices are crucial components of pediatric care. Early screening enables risk stratification, facilitates timely initiation of primary prophylaxis, and significantly reduces the incidence of first variceal bleeding episodes-events associated with substantial morbidity in children. In addition, early detection of the underlying cause allows for more effective medical, surgical, or interventional radiologic management and may prevent long-term complications. Improved non-invasive models and imaging markers continue to support safer, more accessible strategies for monitoring children at risk and reducing dependence on endoscopy. Given the lifelong implications of chronic portal hypertension and the potential for life-threatening bleeding, establishing reliable early predictors of esophageal varices remains a central goal in pediatric hepatology and is essential for optimizing long-term outcomes in affected children.
- Conditions
- Esophageal Varices, Portal Hypertension
- Medical subject headings
- Esophageal and Gastric Varices, Hypertension, Portal
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Receiver Operating Characteristic (AUROC) Curve of non-invasive markers for predicting esophageal varices in children with portal hypertension
The AUROC will be used as the aggregate reported value to represent the diagnostic performance of the following markers: platelet count, spleen size z-score, platelet-to-spleen ratio, AST-to-Platelet Ratio Index (APRI), FIB-4 score, and King score. Using the AUROC combines sensitivity and specificity across all possible cut-off values into a single statistical measure of diagnostic accuracy for predicting the presence and grade of esophageal varices. Esophagogastroduodenoscopy (EGD) will serve as the reference (gold standard) method for detecting and grading esophageal varices.
Measured: Baseline
Secondary outcomes (1)
Correlation between non-invasive markers and endoscopic grade of esophageal varices in children with portal hypertension
The relationship between non-invasive markers (platelet count, spleen size z-score, platelet-to-spleen size ratio, CPR, APRI, FIB-4 score, and King score) and the endoscopic grade of esophageal varices (Grade I-III) will be analyzed using Spearman correlation analysis to determine the strength of association between marker values and variceal grade.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2026
- Study start20 Mar 2026 (estimated)
- Primary completion20 Mar 2028 (estimated)
- Study completion20 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophageal VaricesStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 51 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mennat-Allah Hesham Abdelraheem, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07464522
- Sponsor's protocol ID
- Non-invasive predictors of O.V
- Status last verified
- Mar 2026
- First submitted
- 2 Mar 2026
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-invasive Predictors of Esophageal Varices in Pediatric Portal Hypertension and Their Correlation to Upper Endoscopic Findings
- ClinicalTrials.gov ID
- NCT07464522
- Acronym / sponsor ID
- Non-invasive predictors of O.V
- Conditions
- Esophageal Varices, Portal Hypertension
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 51 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 20 Mar 2026 (estimated)
- Primary completion
- 20 Mar 2028 (estimated)
- Study completion
- 20 May 2028 (estimated)
- First posted
- 11 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study:
- To evaluate the diagnostic accuracy of non-invasive markers in predicting the presence and grading of esophageal varices in children with portal hypertension.
- To correlate these non-invasive markers with the severity of portal hypertension and the grade of esophageal varices to identify patients at high risk of bleeding.
- To propose a defined protocol for screening esophageal varices in those children.
Detailed description
Portal hypertension in children represents a major hepatobiliary disorder characterized by abnormally elevated pressure within the portal venous system, typically defined as a clinically significant increase in portal venous pressure leading to the formation of portosystemic collaterals and complications such as splenomegaly, hypersplenism, gastroesophageal varices, and portal hypertensive gastropathy. Although direct portal pressure measurement is rarely performed in pediatrics, portal hypertension is generally inferred when clinical, laboratory, and radiologic findings indicate increased resistance to portal blood flow. Doppler ultrasonography demonstrating reduced portal vein velocity, increased portal vein diameter, or reversal of flow is widely accepted as a non-invasive surrogate of elevated portal pressure in children.
The true global incidence of pediatric portal hypertension remains difficult to determine, partly because of variations in underlying etiologies across different regions. Nevertheless, portal hypertension is a major cause of upper gastrointestinal bleeding in childhood, accounting for a significant proportion of variceal hemorrhage admissions in tertiary pediatric gastroenterology units. In developing countries, extrahepatic portal vein obstruction (EHPVO) constitutes the leading cause, whereas intrahepatic diseases dominate in high-income nations. With increasing survival of children with chronic liver diseases and improved neonatal care, the burden of pediatric portal hypertension has been rising over the past two decades, underscoring the need for improved strategies for early diagnosis and prevention of complications.
Causes of portal hypertension in children are traditionally divided into extrahepatic and intrahepatic categories. EHPVO is among the most frequent etiologies in many low- and middle-income countries and is commonly associated with neonatal umbilical vein catheterization, sepsis, dehydration, thrombophilia, abdominal surgery, and congenital portal vein malformations. These children often present at a young age with splenomegaly and hypersplenism despite preserved liver synthetic function. Intrahepatic causes include cholestatic liver diseases such as biliary atresia-which remains a leading indication for pediatric liver transplantation-congenital hepatic fibrosis, autoimmune hepatitis, Wilson disease, alpha-1-antitrypsin deficiency, metabolic disorders, and chronic viral hepatitis.
Progressive hepatocellular injury, fibrosis, and architectural distortion increase resistance to portal flow and lead to portal hypertension in these conditions.
Diagnosis of portal hypertension in children relies on a combination of clinical evaluation, laboratory abnormalities, and imaging findings. Splenomegaly is the most common and often earliest clinical manifestation. Laboratory markers such as thrombocytopenia reflect hypersplenism secondary to splenic sequestration. Doppler ultrasound is the first-line diagnostic tool, providing information on portal vein diameter, patency, flow velocity, degree of congestion, presence of cavernous transformation, and detection of portosystemic collaterals. Additional imaging modalities such as contrast-enhanced CT, MR angiography, and elastography may assist in defining the underlying cause and assessing liver stiffness. Endoscopy remains the gold standard for confirming and grading esophageal varices; however, its invasive nature and the need for anesthesia in children limit its use as a routine screening tool. Consequently, numerous non-invasive predictors such as platelet count, spleen size, platelet-to-spleen ratio, APRI, liver stiffness, and composite scores have been investigated to reduce reliance on endoscopy.
Complications of pediatric portal hypertension vary according to etiology and disease stage. Esophageal and gastric varices represent the most feared sequelae, with variceal hemorrhage contributing significantly to morbidity and mortality. Other complications include portal hypertensive gastropathy, hypersplenism, ascites, growth failure, minimal hepatic encephalopathy, and portal biliopathy in cases of long-standing EHPVO. Extrahepatic consequences such as portopulmonary hypertension and hepatopulmonary syndrome are increasingly recognized in children with chronic liver disease and may adversely affect prognosis, transplant eligibility, and overall quality of life.
The early diagnosis of portal hypertension and timely identification of esophageal varices are crucial components of pediatric care. Early screening enables risk stratification, facilitates timely initiation of primary prophylaxis, and significantly reduces the incidence of first variceal bleeding episodes-events associated with substantial morbidity in children. In addition, early detection of the underlying cause allows for more effective medical, surgical, or interventional radiologic management and may prevent long-term complications. Improved non-invasive models and imaging markers continue to support safer, more accessible strategies for monitoring children at risk and reducing dependence on endoscopy. Given the lifelong implications of chronic portal hypertension and the potential for life-threatening bleeding, establishing reliable early predictors of esophageal varices remains a central goal in pediatric hepatology and is essential for optimizing long-term outcomes in affected children.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Portal hypertension in children will be defined using non-invasive clinical, laboratory, and Doppler-ultrasound criteria, in the context of clinical presentation, without invasive pressure measurements. Patients with portal hypertension will be classified as: patients with hepatic causes and patients with extrahepatic causes All patients included in this study will be subjected to: * 1. Full Clinical History * 2. Detailed Clinical Examination * 3. Laboratory Investigations * 4. Abdominal Ultrasound * 5. Doppler Ultrasound * 6.Non-invasive predictive scores for esophageal varices The following parameters will be assessed: * Platelet count (PLT) * Spleen size z-score * Platelet count to spleen size ratio: * CPR (Calculated Platelet Ratio) * APRI (AST to Platelet Ratio Index) * FIB-4 * King score * MELD and PELD scores will be analyzed as secondary variables and not as primary predictors of esophageal varices -7. Esophagogastroduodenoscopy (EGD)
Key inclusion criteria (1 listed)
- Patients aged less than 18 years diagnosed with portal hypertension either due to hepatic or extrahepatic causes
Key exclusion criteria (5 listed)
- Active variceal bleeding at presentation (hemodynamic instability affects platelet/spleen parameters).
- Previous history of variceal bleeding or endoscopic intervention (band ligation/sclerotherapy).
- Prior surgical portosystemic shunts or Transjugular Intrahepatic Portosystemic Shunt (TIPS).
- Current use of vasoactive drugs for primary prophylaxis (e.g., Non-selective beta-blockers).
- Systemic infections or hematological disorders causing independent thrombocytopenia or splenomegaly (to avoid confounding the platelet/spleen ratio).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Area Under the Receiver Operating Characteristic (AUROC) Curve of non-invasive markers for predicting esophageal varices in children with portal hypertension
Time frame: Baseline
The AUROC will be used as the aggregate reported value to represent the diagnostic performance of the following markers: platelet count, spleen size z-score, platelet-to-spleen ratio, AST-to-Platelet Ratio Index (APRI), FIB-4 score, and King score. Using the AUROC combines sensitivity and specificity across all possible cut-off values into a single statistical measure of diagnostic accuracy for predicting the presence and grade of esophageal varices. Esophagogastroduodenoscopy (EGD) will serve as the reference (gold standard) method for detecting and grading esophageal varices.
1 secondary outcome
Correlation between non-invasive markers and endoscopic grade of esophageal varices in children with portal hypertension
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Esophageal Varices
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Enrolling by invitationObservational study
Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils
Arteriovenous Malformation, Gastrointestinal Bleed
Not yet recruitingObservational study
Baveno VIII Criteria for Portal Hypertension in Egyptian Patients
Compensated Liver Disease, Esophageal Varices
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.
Esophageal Varices
Not yet recruitingObservational study
Clinical Trial to Evaluate the Effectiveness of Liver Shear Wave Quantization Detector Spleen Stiffness Value in the Diagnosis of Esophageal Varices
Chronic Liver Diseases, Spleen Stiffness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Esophageal Varices and Portal Hypertension, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mennat-Allah H Abdelraheem, MD (+201061811080, menna128hesham1712@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area Under the Receiver Operating Characteristic (AUROC) Curve of non-invasive markers for predicting esophageal varices in children with portal hypertension (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.